Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 20/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5436183 | 0.99 | TRPV1 (0.54) | TRPV1 | |
| SCHEMBL5432617 | 0.98 | TRPV1 (0.56) | TRPV1 | |
| SCHEMBL5426956 | 0.95 | TRPV1 (0.58) | TRPV1 | |
| SCHEMBL5429784 | 0.95 | TRPV1 (0.57) | TRPV1 | |
| SCHEMBL5433071 | 0.93 | TRPV1 (0.50) | TRPV1 | |
| SCHEMBL5431112 | 0.93 | TRPV1 (0.55) | TRPV1 | |
| SCHEMBL5440160 | 0.92 | TRPV1 (0.54) | TRPV1 | |
| SCHEMBL5436214 | 0.92 | TRPV1 (0.65) | TRPV1 | |
| SCHEMBL5432601 | 0.91 | TRPV1 (0.51) | TRPV1 | |
| SCHEMBL5433034 | 0.91 | TRPV1 (0.58) | TRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070219203-A1 | Arylalkylamino-substituted quinazoline analogues | NEUROGEN CORPORATION (US) | 2007-09-20 | — | — | US | disclosed |
| US-20070219203-A1 | Arylalkylamino-substituted quinazoline analogues | NEUROGEN CORPORATION (US) | 2007-09-20 | — | — | US | disclosed |
| US-20070219203-A1 | Arylalkylamino-substituted quinazoline analogues | NEUROGEN CORPORATION (US) | 2007-09-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070219203-A1 | Arylalkylamino-substituted quinazoline analogues | PIGS, GPR35, HRH4 | TRPV1 358/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.